On Thursday, H.C. Wainwright analyst Swayampakula Ramakanth increased the price target for MediWound Ltd (NASDAQ: MDWD) shares to $31 from $25, while keeping a Buy rating on the stock. Currently ...

Image source: The Motley Fool. DATE Wednesday, May 21, 2025, at 8:30 a.m. EDT Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. CALL ...

YAVNE, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for ...

YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a $201.56 million market cap company specializing in enzymatic therapeutics for tissue repair, announced findings from a post hoc analysis published in ...

MediWound publishes analysis showing EscharEx® outperforms SANTYL® in treating venous leg ulcers, highlighting faster debridement and wound healing.

--MediWound Ltd., a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. Cyaandi Dove, DPM, of ...

Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL®YAVNE, Israel, May 13, 2025 (GLOBE ...

Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL®YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE ...

The analysis is based on data from the Company's Phase II ChronEx clinical trial in patients with venous leg ulcers (VLUs) evaluating the efficacy and safety of EscharEx ® compared with collagenase ...

Presentations at WHS and SAWC to highlight EscharEx’s mechanism of action, preclinical advantages over SANTYL®, and new data in treating VLUs and DFUs Findings reinforce the ongoing Phase III ...

Completed a head-to-head comparative analysis of EscharEx vs. SANTYL ® from a Phase II trial, demonstrating EscharEx's superiority in key clinical outcomes.

The Business Research Company's Santyl Global Market Report 2025 – Market Size, Trends, And Forecast 2025-2034 Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase ...